For patients with advanced or metastatic solid tumors Etigilimab is an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT is a next generation checkpoint receptor shown to block T-cell activation and the body’s natural anti-cancer immune response. Etigilimab is an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells with a goal of improving the activation and effectiveness of T-cell and NK cell anti-tumor activity.
The TIGIT immune receptor is a promising new target for cancer immunotherapy. We welcome the opportunity to collaborate with Mereo to jumpstart the clinical assessment of etigilimab in clear cell ovarian cancer, which lacks effective treatment options once advanced."
Ross Barrett, Managing Director, Cancer Focus Fund
Mereo completed a Phase 1a dose escalation clinical trial with Etigilimab in patients with advanced solid tumors and enrolled patients in a Phase 1b study in combination with nivolumab in selected tumor types.
23 patients were treated in the Phase 1a dose escalation study with doses up to 20 mg/kg Q2W. Tumor types included colorectal cancer, endometrial cancer, pancreatic cancer and other tumors. No dose limiting toxicities were observed. In the Phase 1b combination study, a total of ten patients, nine of whom had progressed on prior anti-PD-1/PD-L1 therapies were enrolled at doses of 3, 10, and 20 mg/kg. Eight patients were evaluable for tumor growth assessment, and all of these patients had progressed on PD-1/PD-L1 therapies with best responses including one patient with a partial response another with stable disease. These patients remained on study for up to 224 days. No dose limiting toxicities (DLTs) were observed and the most common related adverse events included fatigue, rash, and pruritis.
We initiated ACTIVATE, a Phase 1b/2 basket combination study of etigilimab in combination with nivolumab in select recurrent advanced / metastatic solid tumors.
Early results are highly encouraging, with promising interim efficacy, safety, and biomarker data.
| Efficacy | Safety | Biomarker Data |
|
|
|
Continued evaluation of the combination of Etigilimab with an anti-PD-1 antibody is supported by these data
Mereo BioPharma today reported promising interim efficacy, safety, and biomarker data on patients from ACTIVATE, a Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with nivolumab in select recurrent advanced / metastatic solid tumors
Mereo BioPharma today announced it will host a virtual R&D day on Thursday, May 13, 2021 to review the Company’s etigilimab (Anti-TIGIT) program.
Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors
One complete response, one partial response and four cases of stable disease observed among 15 patients in the efficacy analysis set
Etigilimab was well tolerated with a favorable safety profile
Conference call today at 8:30am ET
